← Back to Home

Five Years After a Single Chikungunya Vaccine Dose, 94% of Those Evaluated Still Maintain an Antibody Response

Follow-up results for IXCHIQ add five-year evidence on immune persistence, but meeting the antibody threshold cannot be directly translated into protection against disease.

By SURL BioNews

For chikungunya, whose outbreaks are difficult to predict, how long the immune response lasts after vaccination is an important question for prevention planning. Valneva announced on November 10 that five years after a single dose of IXCHIQ, 94% of evaluated adults still met the predefined antibody response threshold, adding data on the vaccine’s long-term immune persistence.

According to the same announcement published on the company’s website and through GlobeNewswire, 221 healthy adults were available for evaluation at year five in the VLA1553-303 trial. The company said antibody persistence among those aged 65 and older was similar to that among adults aged 18 to 64, with similar antibody geometric mean titers and seroresponse rates in both groups. However, the announcement did not report the number of participants in each age group or complete statistical intervals.

“Seroresponse” here has a specific laboratory definition: a neutralizing antibody titer of at least 150, measured using a micro plaque reduction neutralization test (µPRNT50). This test assesses the ability of serum to inhibit viral infection of cells. According to the company, the threshold was an assessment endpoint agreed with regulators under the accelerated approval pathway.

The 94% figure therefore represents the proportion of those evaluated at five years who still met the antibody threshold; it cannot be interpreted as 94% vaccine efficacy against disease. This announcement focused on whether the immune response persists. It did not provide a comparison of disease incidence between vaccinated and unvaccinated people, and this figure alone is insufficient to determine when a booster dose is needed.

Chikungunya virus is transmitted by infected Aedes mosquitoes and can cause fever and severe joint pain. In some patients, joint symptoms may persist for a long time. If a single dose can provide long-term protection, it would help with prevention planning in endemic areas and for travel. The current antibody results support this possibility, while the actual degree of protection still needs to be established through clinical and real-world data.

Valneva said a pilot vaccination program conducted by Brazil’s Ministry of Health and the Butantan Institute from February to October 2026 had vaccinated nearly 80,000 adults aged 18 to 59 with IXCHIQ and would serve as the basis for subsequent post-marketing studies. These studies are expected to provide effectiveness and safety data. The five-year antibody announcement itself did not answer either question, and similar antibody responses in older adults cannot be used to directly infer similar safety.

VLA1553-303 is funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and the EU’s Horizon Europe program, with follow-up scheduled to continue until ten years after vaccination. At this stage, the evidence still comes from a company announcement; the two publication channels do not constitute independent verification. Full study results will help clarify how loss to follow-up and age differences affect the applicability of these five-year data.

References

  1. Valneva
  2. Valneva SE via GlobeNewswire